Cerevel Therapeutics Holdings, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — |
| Operating income | −$447.3M | −$367.8M | −$220.1M | −$149.1M | −$83.5M |
| Net income | −$432.8M | −$351.5M | −$225.3M | −$152.1M | −$128.4M |
| Total assets | $1.24B | $1.02B | $688.9M | $445.3M | $120.8M |
| Total liabilities | $569.6M | $496.6M | $110.2M | $60.8M | $43.0M |
| Equity | $673.7M | $521.2M | $578.7M | $384.5M | $77.8M |
| EPS (diluted) | $-2.67 | $-2.32 | $-1.65 | $-2.01 | — |
| Shares out. | 156.7M | 148.0M | 127.3M | 127.1M | 60.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- —
- Net margin
- —
- Return on equity
- −64.2%
- Return on assets
- −34.8%
- Return on capital (ROCE)
- −38.9%
- Liabilities / assets
- 45.8%
- Debt / equity
- 0.85×
- Book value / share
- $4.30
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -0.02distress
- Accruals / assets
- −7.3%clean
- Piotroski F-Score
- 2/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Pfizer Inc | Aug 1, 2024 | U | 27.3M | $45.00 |
| Bain Capital Investors LlcDirector | Aug 1, 2024 | D | 65.7M | — |
| Gordon Christopher RDirector | Aug 1, 2024 | D | 3,282 | — |
| Koppel AdamDirector | Aug 1, 2024 | D | 3,282 | — |
| Sanchez RamiroOfficer — Chief Medical Officer | Aug 1, 2024 | D | 14,673 | — |
| Giordano Douglas E.Director | Aug 1, 2024 | D | 3,282 | — |
| Renaud Ronald C JrOfficer — President & CEO | Aug 1, 2024 | D | 160,452 | — |
| Mckernan RuthDirector | Aug 1, 2024 | D | 3,282 | — |
| Akamine ScottOfficer — Chief Legal Officer | Aug 1, 2024 | D | 7,527 | — |
| Sulzberger GabrielleDirector | Aug 1, 2024 | D | 48,415 | — |
| Renger JohnOfficer — Chief Scientific Officer | Aug 1, 2024 | D | 6,370 | — |
| Dipietro KennethOfficer — Chief Human Resources Officer | Aug 1, 2024 | D | 25,042 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventAug 1, 2024
- Shareholder vote · Other material eventFeb 16, 2024
- Entered a material agreement · Regulation FD disclosure · Other material eventDec 7, 2023
- Results of operationsNov 1, 2023
- Entered a material agreement · Other material eventOct 12, 2023
- Results of operations · Regulation FD disclosureOct 11, 2023
- Results of operationsAug 2, 2023
- Shareholder voteJun 8, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.